Abstract

Primary antiphospholipid syndrome (PAPS) is a life-threatening clotting disorder mediated by pathogenic autoantibodies. Here we dissect the origin of self-reactive B cells in human PAPS using peripheral blood and bone marrow of patients with triple-positive PAPS via combined single-cell RNA sequencing, B cell receptors (BCR) repertoire profiling, CITEseq analysis and single cell immortalization. We find that antiphospholipid (aPL)-specific B cells are present in the naive compartment, polyreactive, and derived from the natural repertoire. Furthermore, B cells with aPL specificities are not eliminated in patients with PAPS, persist until the memory and long-lived plasma cell stages, likely after defective germinal center selection, while becoming less polyreactive. Lastly, compared with the non-PAPS cells, PAPS B cells exhibit distinct IFN and APRIL signature as well as dysregulated mTORC1 and MYC pathways. Our findings may thus elucidate the survival mechanisms of these autoreactive B cells and suggest potential therapeutic targets for the treatment of PAPS.

Primary antiphospholipid syndrome (PAPS) is a clotting disorder attributed to autoreactive antibodies produced by B cells. Here the authors show, using single cell omics and B cell repertoire data, that autoreactive B cells originate from the natural B cell repertoire and escape germinal center selection to persist in PAPS patient via potential dysregulation of mTORC1 and MYC pathways.

Details

Title
Defective germinal center selection results in persistence of self-reactive B cells from the primary to the secondary repertoire in Primary Antiphospholipid Syndrome
Author
Dieudonné, Yannick 1   VIAFID ORCID Logo  ; Lorenzetti, Raquel 2 ; Rottura, Julien 3 ; Janowska, Iga 4   VIAFID ORCID Logo  ; Frenger, Quentin 3   VIAFID ORCID Logo  ; Jacquel, Léa 1   VIAFID ORCID Logo  ; Vollmer, Olivier 1 ; Carbone, Francesco 5   VIAFID ORCID Logo  ; Chengsong, Zhu 6   VIAFID ORCID Logo  ; Luka, Marine 5 ; Depauw, Sabine 7 ; Wadier, Nadège 7 ; Giorgiutti, Stéphane 1   VIAFID ORCID Logo  ; Nespola, Benoît 8 ; Herb, Agathe 9   VIAFID ORCID Logo  ; Voll, Reinhard Edmund 4   VIAFID ORCID Logo  ; Guffroy, Aurélien 1 ; Poindron, Vincent 10 ; Ménager, Mickaël 5   VIAFID ORCID Logo  ; Martin, Thierry 1 ; Soulas-Sprauel, Pauline 11 ; Rizzi, Marta 12   VIAFID ORCID Logo  ; Korganow, Anne-Sophie 1 ; Gies, Vincent 11   VIAFID ORCID Logo 

 Strasbourg University Hospital, Department of Clinical Immunology and Internal Medicine, National Reference Center for Systemic Autoimmune Diseases (CNR RESO), Tertiary Center for Primary Immunodeficiency, Strasbourg, France (GRID:grid.11843.3f) (ISNI:0000 0001 2157 9291); Fédération de Médecine Translationnelle de Strasbourg (FMTS), INSERM UMR - S1109, Institut thématique interdisciplinaire (ITI) de Médecine de Précision de Strasbourg, Transplantex NG, Fédération Hospitalo-Universitaire OMICARE, Strasbourg, France (GRID:grid.11843.3f) (ISNI:0000 0001 2157 9291); Faculty of Medicine, Université de Strasbourg, Strasbourg, France (GRID:grid.11843.3f) (ISNI:0000 0001 2157 9291) 
 University of Freiburg, Center for Chronic Immunodeficiency, Medical Center University of Freiburg, Faculty of Medicine, Freiburg, Germany (GRID:grid.5963.9) (ISNI:0000 0004 0491 7203); University of Freiburg, Department of Rheumatology and Clinical Immunology, Medical Center, Faculty of Medicine, Freiburg, Germany (GRID:grid.5963.9) (ISNI:0000 0004 0491 7203); Medical University of Graz, Division of Rheumatology and Clinical Immunology, Graz, Austria (GRID:grid.11598.34) (ISNI:0000 0000 8988 2476) 
 Fédération de Médecine Translationnelle de Strasbourg (FMTS), INSERM UMR - S1109, Institut thématique interdisciplinaire (ITI) de Médecine de Précision de Strasbourg, Transplantex NG, Fédération Hospitalo-Universitaire OMICARE, Strasbourg, France (GRID:grid.11843.3f) (ISNI:0000 0001 2157 9291); Faculty of Life Sciences, Université de Strasbourg, Strasbourg, France (GRID:grid.11843.3f) (ISNI:0000 0001 2157 9291) 
 University of Freiburg, Center for Chronic Immunodeficiency, Medical Center University of Freiburg, Faculty of Medicine, Freiburg, Germany (GRID:grid.5963.9) (ISNI:0000 0004 0491 7203); University of Freiburg, Department of Rheumatology and Clinical Immunology, Medical Center, Faculty of Medicine, Freiburg, Germany (GRID:grid.5963.9) (ISNI:0000 0004 0491 7203) 
 INSERM UMR 1163, Université Paris Cité, Institut Imagine, Laboratory of Inflammatory Responses and Transcriptomic Networks in Diseases, Atip-Avenir Team, Paris, France (GRID:grid.7429.8) (ISNI:0000000121866389) 
 University of Texas Southwestern Medical Center, Department of Immunology, Microarray and Immune Phenotyping Core Facility, Dallas, USA (GRID:grid.267313.2) (ISNI:0000 0000 9482 7121) 
 Fédération de Médecine Translationnelle de Strasbourg (FMTS), INSERM UMR - S1109, Institut thématique interdisciplinaire (ITI) de Médecine de Précision de Strasbourg, Transplantex NG, Fédération Hospitalo-Universitaire OMICARE, Strasbourg, France (GRID:grid.11843.3f) (ISNI:0000 0001 2157 9291) 
 Strasbourg University Hospital, Laboratoire d’Immunologie, Plateau technique de Biologie, Strasbourg, France (GRID:grid.412220.7) (ISNI:0000 0001 2177 138X) 
 Strasbourg University Hospital, Hematology laboratory, Strasbourg, France (GRID:grid.412220.7) (ISNI:0000 0001 2177 138X) 
10  Strasbourg University Hospital, Department of Clinical Immunology and Internal Medicine, National Reference Center for Systemic Autoimmune Diseases (CNR RESO), Tertiary Center for Primary Immunodeficiency, Strasbourg, France (GRID:grid.11843.3f) (ISNI:0000 0001 2157 9291) 
11  Strasbourg University Hospital, Department of Clinical Immunology and Internal Medicine, National Reference Center for Systemic Autoimmune Diseases (CNR RESO), Tertiary Center for Primary Immunodeficiency, Strasbourg, France (GRID:grid.11843.3f) (ISNI:0000 0001 2157 9291); Fédération de Médecine Translationnelle de Strasbourg (FMTS), INSERM UMR - S1109, Institut thématique interdisciplinaire (ITI) de Médecine de Précision de Strasbourg, Transplantex NG, Fédération Hospitalo-Universitaire OMICARE, Strasbourg, France (GRID:grid.11843.3f) (ISNI:0000 0001 2157 9291); Faculty of Pharmacy, Université de Strasbourg, Illkirch, France (GRID:grid.11843.3f) (ISNI:0000 0001 2157 9291) 
12  University of Freiburg, Center for Chronic Immunodeficiency, Medical Center University of Freiburg, Faculty of Medicine, Freiburg, Germany (GRID:grid.5963.9) (ISNI:0000 0004 0491 7203); University of Freiburg, Department of Rheumatology and Clinical Immunology, Medical Center, Faculty of Medicine, Freiburg, Germany (GRID:grid.5963.9) (ISNI:0000 0004 0491 7203); Medical University of Vienna, Division of Clinical and Experimental Immunology, Institute of Immunology, Center for Pathophysiology, Infectiology and Immunology, Vienna, Austria (GRID:grid.22937.3d) (ISNI:0000 0000 9259 8492); University of Freiburg, CIBSS – Centre for Integrative Biological Signaling Studies, Freiburg, Germany (GRID:grid.5963.9) (ISNI:0000 0004 0491 7203) 
Pages
9921
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3128898189
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.